Treatment

The American Society of Clinical Oncology (ASCO) and ONS are conducting an ongoing collaborative project to use a rigorous, consensus-based process to develop standards for safe administration of chemotherapy.
This extensive drug table describes the drug and food interactions associated with many oral therapies for cancer.
View this 16-minute presentation to learn how chemotherapy doses are calculated.
C.D. is a 71‐year‐old man who was diagnosed with multiple myeloma six weeks ago. At the time of diagnosis, several comorbidities were noted:
A.B. is a 61‐year‐old woman with metastatic HER2‐positive breast cancer. She is a self-employed consultant and travels extensively in the United States and internationally to work with her diverse clients. She is divorced and has three adult married children. She is active, in good health, and has no comorbid conditions. A.B.
Patients can have multiple risk factors for developing neutropenia, including type of chemotherapy or radiation, doses, and administration schedule of the treatment regimen.
Following is "Practice Safe Nursing With Oral Hazardous Drugs," an article featured in the January 2010 issue of ONS Connect. 
Oral formulations of chemotherapy and hormonal therapies have been used for decades and include many familiar agents, such as cyclophosphamide, melphalan, and tamoxifen.
This slideshow discusses evidence-based interventions for managing neutropenia.
"Oncology Nurses' Use of National Comprehensive Cancer Network Clinical Practice Guidelines for Chemotherapy-Induced and Febrile Neutropenia," available as a journal article and podcast, summarizes findings fr
This brief slideshow provides an overview of the causes of neutropenia, as related to chemotherapy and other incidences. 
From prevention and identification of risk status to the development and use of targeted therapies, genetics is changing the face of oncology care. ONS offers many resources for nurses to learn more about genetics (the study of individual genes) and genomics (the study of all genes in the human genome).
Vincristine sulfate is a vesicant. Therefore, it is extremely critical that the IV needle or catheter is properly inserted prior to the vincristine injection or infusion. Any leakage into surrounding tissues during the infusion may cause substantial injury.
There are several very critical points to be aware of when administering vincristine sulfate, also commonly known as Vincasar PFS and Oncovin.
Vincristine sulfate for injection is the salt of an alkaloid from the flowering periwinkle plant (also known as Vinca rosea Linn). It was originally known as leurocristine and is now sometimes also referred to as LCR or VCR. The trade name for vincristine is Vincasar PFS®; the drug is also commonly known as Oncovin.

Pages


Menu